Biotech · Public company · Carlsbad, CA, US
Tyra Biosciences, Inc.
Ticker TYRA · SEC CIK 0001863127
Track this companyFree. Adds Tyra Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials66 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline14
- Dabogratinib (TYRA-300) 60mgPhase 2 · Low Grade Upper Tract Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Dabogratinib (TYRA-300) 80mgPhase 2 · Low Grade Upper Tract Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TYRA-300Phase 2 · Locally Advanced Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TYRA-300 0.125 mg/kgPhase 2 · AchondroplasiaClinicalTrials.gov · fetched Nov 12, 2026
- TYRA-300 0.25 mg/kgPhase 2 · AchondroplasiaClinicalTrials.gov · fetched Nov 12, 2026
- TYRA-300 0.375 mg/kgPhase 2 · AchondroplasiaClinicalTrials.gov · fetched Nov 12, 2026
- TYRA-300 0.50 mg/kgPhase 2 · AchondroplasiaClinicalTrials.gov · fetched Nov 12, 2026
- TYRA-300 0.625 mg/kgPhase 2 · AchondroplasiaClinicalTrials.gov · fetched Nov 12, 2026
- TYRA-300 50mgPhase 2 · Low-grade NMIBCClinicalTrials.gov · fetched Nov 12, 2026
- TYRA-300 60mgPhase 2 · Low-grade NMIBCClinicalTrials.gov · fetched Nov 12, 2026
- TYRA-300 Dose 70 mgPhase 2 · Low-grade NMIBCClinicalTrials.gov · fetched Nov 12, 2026
- Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cyclesPhase 1 · Locally Advanced CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cyclesPhase 1 · Locally Advanced CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TYRA-430Phase 1 · Metastatic Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaPHASE2 · RECRUITING · started Dec 22, 2025ClinicalTrials.gov NCT07265947 · fetched Nov 12, 2026
- Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerPHASE2 · RECRUITING · started Jun 27, 2025ClinicalTrials.gov NCT06995677 · fetched Nov 12, 2026
- Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway AberrationsPHASE1 · RECRUITING · started Apr 24, 2025ClinicalTrials.gov NCT06915753 · fetched Nov 12, 2026
- A Study of TYRA-300 in Children With Achondroplasia: BEACH301PHASE2 · RECRUITING · started Mar 4, 2025ClinicalTrials.gov NCT06842355 · fetched Nov 12, 2026
- Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene AlterationsPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 22, 2023ClinicalTrials.gov NCT06160752 · fetched Nov 12, 2026
- Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 22, 2022ClinicalTrials.gov NCT05544552 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 9, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 2, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 4, 2026 · fetched Nov 12, 2026